Viridian Therapeutics, Inc.

DB:1S1 Stock Report

Market Cap: €1.5b

Viridian Therapeutics Valuation

Is 1S1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1S1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

€358.44
Fair Value
95.0% undervalued intrinsic discount
16
Number of Analysts

Below Fair Value: 1S1 (€17.88) is trading below our estimate of fair value (€358.44)

Significantly Below Fair Value: 1S1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1S1?

Key metric: As 1S1 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1S1. This is calculated by dividing 1S1's market cap by their current book value.
What is 1S1's PB Ratio?
PB Ratio5.4x
BookUS$326.28m
Market CapUS$1.77b

Price to Book Ratio vs Peers

How does 1S1's PB Ratio compare to its peers?

The above table shows the PB ratio for 1S1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average9.4x
7ZT Hamlet BioPharma
25.4xn/a€938.1m
BIO3 Biotest
2.2xn/a€1.4b
BIO3 Biotest
2.3xn/a€1.3b
HPHA Heidelberg Pharma
7.8x-11.43%€144.9m
1S1 Viridian Therapeutics
5.4x49.81%€1.8b

Price-To-Book vs Peers: 1S1 is good value based on its Price-To-Book Ratio (5.4x) compared to the peer average (9.4x).

Price to Book Ratio vs Industry

How does 1S1's PB Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
MDG1 Medigene
0.1x14.15%US$2.07m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
1S1 5.4xIndustry Avg. 3.1xNo. of Companies6PB00.61.21.82.43+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 1S1 is expensive based on its Price-To-Book Ratio (5.4x) compared to the European Biotechs industry average (3.1x).

Price to Book Ratio vs Fair Ratio

What is 1S1's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1S1 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1S1's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1S1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€17.88
€32.24
+80.34%
25.20%€51.92€16.17n/a16
Sep ’26€15.46
€32.32
+109.12%
25.20%€52.05€16.21n/a16
Aug ’26€15.06
€33.09
+119.70%
25.90%€52.68€16.41n/a16
Jul ’26€11.68
€33.94
+190.68%
25.90%€54.03€16.83n/a16
Jun ’26€12.16
€33.94
+179.20%
25.90%€54.03€16.83n/a16
May ’26€11.81
€35.04
+196.86%
23.95%€53.86€19.43n/a16
Apr ’26€12.10
€36.75
+203.72%
23.95%€56.49€20.37n/a16
Mar ’26€14.40
€38.57
+167.83%
23.73%€58.82€21.21n/a16
Feb ’26€19.00
€38.55
+102.91%
23.33%€58.16€20.97n/a16
Jan ’26€18.20
€39.00
+114.30%
23.33%€58.83€21.22n/a16
Dec ’25€20.40
€38.71
+89.74%
21.21%€58.12€20.96n/a16
Nov ’25€19.10
€36.09
+88.93%
21.63%€51.49€20.23n/a16
Oct ’25€20.60
€35.27
+71.19%
21.63%€50.32€19.77€18.0016
Sep ’25€13.30
€31.84
+139.38%
23.25%€41.62€18.10€15.4616
Aug ’25€15.30
€32.61
+113.13%
23.44%€42.63€18.53€15.0616
Jul ’25€11.90
€32.76
+175.26%
23.44%€42.82€18.62€11.6816
Jun ’25€10.80
€33.73
+212.31%
21.69%€42.51€18.48€12.1614
May ’25€12.50
€36.25
+190.01%
12.02%€42.37€27.63€11.8114
Apr ’25€15.80
€36.25
+129.44%
12.02%€42.37€27.63€12.1014
Mar ’25€17.10
€35.68
+108.66%
13.58%€42.45€26.76€14.4015
Feb ’25€17.50
€36.08
+106.18%
14.86%€45.95€26.65€19.0015
Jan ’25€19.90
€35.83
+80.06%
14.84%€45.55€26.42€18.2015
Dec ’24€15.10
€36.59
+142.31%
16.05%€45.97€26.66€20.4015
Nov ’24€11.70
€39.08
+234.00%
16.54%€53.86€28.35€19.1014
Oct ’24€14.10
€40.74
+188.96%
12.55%€53.35€32.76€20.6015
€31.27
Fair Value
42.8% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/05 01:26
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viridian Therapeutics, Inc. is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Kalpit PatelB. Riley Securities, Inc.
Madhu KumarB. Riley Securities, Inc.